Emcure Pharmaceuticals Ltd
EMCUREEmcure Pharmaceuticals Ltd's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it.
Biggest watch item: the price is already 64 weeks into its uptrend — timing risk, not thesis risk.
The price is in a confirmed uptrend (64 weeks in) while the P/E sits at the 57th percentile of its own 2-year range. Underneath, the last four quarters read improving — profit +35.8% year on year, and 133% of the last 3 years' profit arrived as cash. What settles it: the next one or two quarters of delivery.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Emcure Pharmaceuticals Ltd trades at ₹1,951, in a confirmed uptrend and 64 weeks into that stage. That is +14.0% against its own 200-day average. It sits at 92% of a 52-week range of ₹1,355 to ₹2,004. On relative strength it has been ahead of the NIFTY 500 on a trailing-13-week view for 19 straight weeks.
Today the stock is in a confirmed uptrend — week 64 of stage 2, confirmed. At ₹1,951 it trades +14.0% versus its 200-day average and sits at 92% of its 52-week range (₹1,355–₹2,004).
Against the market, two honest reads. Cumulative: over the last 2.2 years the stock moved +43% while the NIFTY 500 moved −3% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 19 straight weeks — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Story check
Emcure Pharmaceuticals Ltd's story is not scored yet against the markers our research file set on 22 August 2026. Where it sits in its own cycle: Not stated in the research file. Our fortnightly research layers last read it on 22 August 2026.
Our read, 22 August 2026. FY26 crossed the $1 billion revenue milestone with PAT up 33%; Q1 FY27 confirmed Zuventus recovery with domestic back to 10.2% growth and PAT up 35.8% — now compounding on a broader base via Europe biosimilars, Novo Nordisk GLP-1, and chronic therapy share gains, at a PE that has compressed 31% from its peak despite rising earnings.
What is proven. FY26 crossed the $1 billion revenue milestone with PAT up 33%; Q1 FY27 confirmed Zuventus recovery with domestic back to 10.2% growth and PAT up 35.8% — now compounding on a broader base via Europe biosimilars, Novo Nordisk GLP-1, and chronic therapy share gains, at a PE that has compressed 31% from its peak despite rising earnings.
What is not proven yet. Two consecutive quarters of domestic revenue below 8% YoY growth (after the Q1 FY27 recovery to 10.2%) would signal the Zuventus restructuring never fully normalized; and gross margin falling below 57% for two consecutive quarters — without management providing a segment-level explanation that fully accounts for the ARV mix — would signal pricing power erosion beyond the structural mix shift.
🚨 What would change our mind. Two consecutive quarters of domestic revenue below 8% YoY growth (after the Q1 FY27 recovery to 10.2%) would signal the Zuventus restructuring never fully normalized; and gross margin falling below 57% for two consecutive quarters — without management providing a segment-level explanation that fully accounts for the ARV mix — would signal pricing power erosion beyond the structural mix shift.
Layer 1 read, 22 August 2026 — KEEP. Twelve quarters without a single down quarter, profit up 36%, and not one accounting flag in four years. Sales have gone from 1,663 Cr to 2,580 Cr a quarter over three years with every quarter beating its year-ago figure, and the newest one grew sales 22.8% and profit 35.8%. The growth is coming from selling more, not from margin tricks — and the proof is that none of the last sixteen quarters carries a single one-off accounting flag, while the cash the business actually generated last year (944 Cr) matched its reported profit (941 Cr) almost exactly. The honest warning: management has missed seven stated commitments across five calls, most recently retreating on its weight-loss drug from 'blockbuster' to 'the jury is still out'. But every one of those misses is a DATE or a product forecast…
What would change Layer 1’s mind. The timeline names two breakers and I keep both, sharpened to what I would actually watch next. First, the domestic business: the September 2026 quarter must show Indian revenue growing 8% or better. It just recovered to 10.2% after the Zuventus reorganisation, and a fall back below 8% would mean that recovery was a one-quarter bounce rather than a fix — that single reading would take this from P1 to P2. Second, and this is the one that would break the thesis rather than downgrade it: gross…
Layer 2 read, 22 August 2026 — ADVANCE. Printed earnings still beat the late-sector warning, but future promises get no credit. The newest quarter reported higher revenue and profit, and cash conversion remains strong over the reported history. The sector's earnings-led move is ⚠ judged context, while its TOPPING lifecycle and cooling social signal lower timing confidence without breaking the stock thesis.
What would change Layer 2’s mind. A current external source showing two quarters below the domestic-growth kill-switch, or pricing pressure that breaches the gross-margin test twice, would flip ADVANCE to DROP.
Layer 3 read, 22 August 2026 — DEPLOY. Deploy small: the business delivers, but management's dates and promises need proof before more capital. Timeline risk R1 is real: seven specific commitments across five calls missed, including repeated debt-free deadlines and product plans. That does not become a management FAIL because reported financial delivery and cash generation remain sound, but it requires VERIFY rather than TRUST. L3 also found managed FX and regulatory exposure plus a May 2026 workforce dispute that the Timeline did not clearly surface.
What would change Layer 3’s mind. A fourth push of the net-cash deadline beyond FY28 without a clear capital-allocation explanation would turn WATCHLIST into management FAIL and force DROP.
CIO read, 22 August 2026 — BENCH. NOT ADMITTED (incoming, benched) · forward-asymmetry 51/100 · CONTESTED. Judged EPS growth of 20.0% only just covers the model-implied 19.7%, leaving a derived +0.3-point gap. The PE is already at the 67th percentile of its own history, while the cash-conversion cycle lengthened to 164 days from 145 days.
🚨 What the surface reading misses. The surface reading is: PE at 34.3x, 38.9th percentile of 10-year range — trading below its own median (34.4x), suggesting the stock is neither expensive nor deeply cheap on trailing earnings. The research reads it further: EPS grew 61% over the same 8 quarters that the PE compressed 27% — the denominator is expanding faster than the market is re-rating the numerator. The cycle_normalized verdict is NA_SHORT_MARGIN_HISTORY (only 3.3 years of post-IPO OPM data), so the full-cycle normalized PE of 38x cannot be read with high confidence. The trailing PE (34.3x) is modestly below the curve median; a trailing PE below the median while EPS compounds at 19% annually is an earnings-led de-rating, not a value-trap.
🚨 What the surface reading misses. The surface reading is: Q3 FY26 PAT growth of 48.1% YoY appears to be an acceleration. The research reads it further: The Q3 FY26 PAT spike to 48.1% partly reflects a low base: Q3 FY25 PAT was Rs 156 Cr, which was below-trend due to integration costs from the Zuventus acquisition. The operating mechanism was real (EBITDA margin expanded 110 bps to 19.5% in Q3, driven by operating leverage and Semaglutide launch momentum), but the base effect explains roughly 15-20% of the apparent acceleration.
Sources: our stock research file (22 August 2026) · quarterly results through Jun 26 · the company’s own earnings calls. The story check is re-scored every results season; the record below never changes.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Emcure Pharmaceuticals Ltd reported ₹2,580 Cr of revenue in the Jun 26 quarter, +22.8% year on year. That is the 9th straight quarter of year-on-year growth. Over 7 years it has compounded at 10.0% a year. The last full year, FY26, came in at ₹9,204 Cr. The last four reported quarters add to ₹9,683 Cr.
FY26 revenue came in at ₹9,204 Cr (+16.6% on the year), capping 7 years at 10.0% compound. The latest quarter (Jun 26) printed ₹2,580 Cr, +22.8% year on year — the 9th consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +18.3% growth against the decade's 10.0% — the current year is running faster than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +18.3% over the last 4 quarters against +18.3%/yr over the last 8 — stabilising; TTM profit +32.2% vs +37.3%/yr — rolling over.
FY26-Q4. revenue ₹2,470 Cr and profit ₹244 Cr as reported.
FY27-Q1. revenue ₹2,580 Cr and profit ₹292 Cr as reported.
Why-sources: our stock research file (22 August 2026) and the company’s own results for those quarters.
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Emcure Pharmaceuticals Ltd's operating margin is 21.0% in the Jun 26 quarter, +1.0 percentage points against the same quarter a year ago. Across 8 fiscal years the operating margin has ranged 14.0% to 24.0%. The current quarter sits inside that band.
The latest quarter's operating margin is 21.0%, +1.0 pp against the same quarter a year ago. Across 8 fiscal years the operating margin has ranged 14.0%–24.0%.
Why the margin moved: operating margin went +0.8 pp year on year while gross margin went −3.4 pp — the gain came mostly from the gross line: input costs and pricing.
FY26-Q4. revenue ₹2,470 Cr and profit ₹244 Cr as reported.
FY27-Q1. revenue ₹2,580 Cr and profit ₹292 Cr as reported.
Why-sources: our stock research file (22 August 2026) and the company’s own results for those quarters.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Emcure Pharmaceuticals Ltd earned ₹292 Cr of net profit in the Jun 26 quarter, +35.8% year on year. It is the 9th consecutive quarter of growth. Full-year FY26 profit was ₹941 Cr. The 7-year compound rate is 24.0%. That is 11.3% of the quarter's revenue. The same quarter a year earlier earned ₹215 Cr.
Jun 26 profit was ₹292 Cr, +35.8% year on year — the 9th consecutive quarter of growth. On the full year, FY26 printed ₹941 Cr (+33.1%), and the 7-year compound rate is 24.0%.
Why profit moved: revenue contributed +22.8% and the margin +1.0 pp — the quarter was revenue-led, with the margin roughly flat.
Pace comparison, last four quarters: profit +33.0% vs revenue +18.3%. Profit is growing faster than sales — fixed costs are being spread over a bigger base, and each extra rupee of revenue drops more to the bottom line.
FY26-Q4. revenue ₹2,470 Cr and profit ₹244 Cr as reported.
FY27-Q1. revenue ₹2,580 Cr and profit ₹292 Cr as reported.
Why-sources: our stock research file (22 August 2026) and the company’s own results for those quarters.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 133% of Emcure Pharmaceuticals Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹944 Cr of operating cash against ₹941 Cr of profit. After ₹633 Cr of capital spending, ₹311 Cr was left as free cash.
FY26: operating cash of ₹944 Cr against reported profit of ₹941 Cr, leaving free cash of ₹311 Cr after ₹633 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 133% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why conversion sits at 133%: the cash cycle tightened 51 days between FY21 and FY26 — cash that used to wait in the cycle now reaches the bank sooner.
Router verdict: the bigger cash user is investment — capital spending ran 1.9× depreciation over three years, so the next section's job is to check what that build-out is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Emcure Pharmaceuticals Ltd's cash conversion cycle runs 161 days in FY26, down from 212 days in FY21. Capital spending ran ₹2,145 Cr over the last 3 years. At FY26 sales of ₹9,204 Cr each day of that cycle holds about ₹25.2 Cr, so roughly ₹4,060 Cr sits inside the business at any moment.
FY26: debtors at 102 days, inventory at 239 days — roughly 7.9 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 161 days, tighter than FY21's 212.
The full loop: cash goes out to suppliers and production on day 0; stock waits 239 days to sell; customers pay about 102 days after that; and suppliers themselves are paid at 180 days — netting out to the 161-day cycle.
In money terms: at FY26 sales of ₹9,204 Cr, each day of the cycle holds about ₹25.2 Cr — so the 161-day loop keeps roughly ₹4,060 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹2,145 Cr over the last 3 fiscal years against ₹1,111 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹273 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.
Emcure Pharmaceuticals Ltd earns a ROCE of 24% in FY26. That is up from a trough of 11% in FY20. A return-on-invested-capital spread against the cost of capital is not computable from what is held here. The wiring behind it is 10.2% net margin on 0.97× asset turns.
FY26 ROCE is 24%, recovered from a FY20 trough of 11% — the full ladder below shows the fall and the climb, undoctored.
Why the return is what it is — the wiring (FY26): 10.2% net margin × 0.97× asset turns × 1.92× balance-sheet leverage ≈ 19.0% on equity. Margin does its share; leverage is a meaningful part of the equation.
The quarterly return curves and the return-on-invested-capital overlay, which only the second data source carries, are not drawn on this page: its two data sources disagree by up to 7.2% on reported income across 12 comparable periods. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.
Debt Debt-to-equity says how much of the business is funded by borrowings; interest cover says how many times operating profit pays the interest bill. Low and high, respectively, is the safe corner.
Emcure Pharmaceuticals Ltd carries ₹1,521 Cr of borrowings against ₹4,950 Cr of equity in FY26, a debt-to-equity of 0.31. Operating profit covers the interest bill 12×. Over 5 years borrowings went from ₹2,310 Cr to ₹1,521 Cr. Capital spending ran ₹2,145 Cr across the last 3 of those years.
FY26: borrowings of ₹1,521 Cr against equity of ₹4,950 Cr — a debt-to-equity of 0.31. Operating profit covers the interest bill 12×. Over 5 years borrowings went from ₹2,310 Cr to ₹1,521 Cr while capital spending ran ₹2,145 Cr in just the last 3 — the build-out is being paid for out of cash, not debt.
The total-debt and debt-to-equity series, which only the second data source carries, are not drawn on this page: its two data sources disagree by up to 7.2% on reported income across 12 comparable periods. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
Domestic institutions added 4.5 points of Emcure Pharmaceuticals Ltd over 7 quarters, the biggest move on the register. That takes domestic institutions to 8.5% of the company. Foreign institutions moved +2.0 points over the same window, to 4.9%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Domestic institutions: +4.5 points over 7 quarters to 8.5%; Foreign institutions: +2.0 points over 7 quarters to 4.9%; Promoters: −0.3 points over 7 quarters to 77.8%.
Why the register moved: domestic institutions drove it (+4.5 points), alongside foreign institutions (+2.0 points) — steady accumulation by institutions reading the same numbers this page reads.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Emcure Pharmaceuticals Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Emcure Pharmaceuticals Ltd trades at 35.9× P/E, mid-range by its own standards (57th percentile). Its long-run median P/E is 35.2×, measured across 2.2 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 35.9× is mid-range by its own standards (57th percentile), against a long-run median of 35.2× measured over 2.2 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Why the multiple sits where it does: over the past year annual EPS moved +35.6% against a +51.9% price move — the price outran earnings, pushing the multiple UP its own range.
Put together: the multiple is unremarkable against its own past, so the story rests on the earnings line underneath it, not the multiple.
The PEG ratio and its quarterly curve, which only the second data source carries, are not drawn on this page: its two data sources disagree by up to 7.2% on reported income across 12 comparable periods. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.
What the price assumes This reading works the multiple backwards. It asks one question: what yearly rate of profit growth is a buyer at the market price already paying for? The number is the growth rate that makes eleven years of profit — six years growing, then five fading — add up to that day's market price, once each year is discounted at 11% a year.
Solved at its 24 August 2026 price, Emcure Pharmaceuticals Ltd was paying for profit growth of about 19.7% a year. Profit itself has compounded 24.0% a year over the past 7 years. Today the market pays 35.9× P/E, the 57th percentile of its own 2-year range.
What the two numbers say together. The multiple is unremarkable against its own past, and the growth the price is paying for is close to what this company has actually delivered.
How to hold this number: it is a reading of one day's price, taken on 24 August 2026, not a running figure — every other number on this page, the multiple included, is read off the live quote as of 25 September 2026. A higher price is paying for more growth and a lower price for less, so it moves whenever the price does, and this page does not restate it between measurements.
Stage: Consistent Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Emcure Pharmaceuticals Ltd reads as consistent on its fundamental arc. Consistent — revenue and profit growth have stayed positive through the window, with ROCE at 24.0% and holding. The read is built from 9 quarters across 3 curves, on partial evidence.
Why it matters: steady curves with healthy returns are the compounding setup — the risk is the price, not the business.
One or more growth curves carry a base-effect spike — a large year-on-year move off a near-zero or loss-making comparable quarter. Those spikes are capped before the classifier reads the trajectory, and shown pinned on the chart, so a single distorted quarter does not drive the stage call.
Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.
A partial read: at least one curve is short, or the returns curve is not the computed quarterly series — hold the stage word a little more loosely.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +16.6% | +15.4% | +12.8% | — |
| Profit | +33.1% | +18.7% | +17.6% | — |
| EPS | +35.6% | +18.3% | +16.1% | — |
| Share price | +51.9% | — | — | — |
4-Factor Sector Score
59.4/100 — rank 9 of 34 in Pharma Formulations · 75% evidence confidence
Emcure Pharmaceuticals Ltd scores 59.4 out of 100 against the 34 companies it is compared with in Pharma Formulations, ranking 9. Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -18.5% and the one-year return is 45.3%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth.
The four contributions add to the total exactly: 25.6 + 18.1 + 10.6 + 5.1 = 59.4. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Said versus delivered
What Emcure Pharmaceuticals Ltd's management promised, set against what actually arrived — 4 tracked promises on the record. Read straight from the company’s own earnings calls. A promise that slipped stays on this page after it is met.
🚨 Semaglutide Outlook Became Materially More Cautious · 6 August 2026. In the February 2026 and May 2026 calls, management expressed strong confidence that Poviztra would change the market and perform well. In the August 2026 call, management said the market outlook remained unresolved and that it could not distinguish channel stuffing from real consumption, representing a material change in confidence relevant to Poviztra's expected contribution. Management cited the crowded launch environment as a risk, but did not reconcile why the earlier strong conviction was expressed despite the known generic competition.
🚨 Amphotericin B Pan-European Launch Scope Fell Short of Prior Commitments · 5 May 2026. In both the Nov 2025 and Feb 2026 calls, management explicitly committed to Amphotericin B launches across Europe by year-end FY26. The latest call (May 2026) confirms that only select European markets were covered in H2 FY26, with broader European and ROW expansion now deferred to FY27. No clear explanation was provided in the latest call for why the pan-European scope was not achieved as consistently promised across two prior calls.
Canada Semaglutide Strategy Pivots from Own Filing to Third-Party Partnership · 5 May 2026. The Nov 2025 call included an explicit on-record confirmation that plans to file Emcure's own semaglutide product in Canada by end of FY26 would proceed as planned. The latest call (May 2026) instead describes a near-term Canadian launch via a Dr. Reddy's distribution partnership for Quebec, while own-product commercialization is repositioned as a mid-term opportunity. The present-tense phrasing 'we are also filing' implies the end-of-FY26 filing commitment was not completed on schedule, and the near-term Canadian GLP-1 strategy has materially shifted from own-product to third-party without explanation.
🚨 Debt Reduction Timeline Extended · 4 February 2026. In the November 2025 call, management explicitly guided that the company would be debt-free within 18 to 24 months (by the end of FY27). However, in the February 2026 call, just one quarter later, this timeline was significantly pushed out to 24 to 36 months without clear justification for the additional year-long delay. Earlier call (Nov 2025): “We expect now to be debt-free by end of next year. So it”. Later call (Feb 2026): “We expect the debt to go off the balance sheet probably in the next 24 to 36 months.”
Every quote above is taken word for word from the company’s own earnings calls.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Kwality Pharmaceuticals Ltd539997 | 72.1/100Favorable setup82% evidence | LEADER | 30.3/35 Revenue 37.9% · PAT 88.4% · OPM change 3 pp 95% evidence | 18.0/25 ROCE 24.1% · OPM 25% 76% evidence | 6.8/20 P/E 46.7× · PEG — 50% evidence | 17.0/20 RS sector 45% · RS bench 105.2% · 1Y 283.3%12 of 12 weeks ahead 100% evidence |
| Exact sum: 30.3 + 18 + 6.8 + 17 = 72.1 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 2Glenmark Pharmaceuticals LtdGLENMARK | 67.1/100Favorable setup100% evidence | BREAKING OUT | 29.9/35 Revenue 32.9% · PAT 100% · OPM change 2 pp 100% evidence | 18.6/25 ROCE 39.8% · OPM 20% 100% evidence | 14.0/20 P/E 21.5× · PEG 1.43 100% evidence | 4.6/20 RS sector -25.4% · RS bench 13.8% · 1Y 14.1%5 of 12 weeks ahead 100% evidence |
| Exact sum: 29.9 + 18.6 + 14 + 4.6 = 67.1 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -25.4% and the one-year return is 14.1%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 3Gland Pharma LtdGLAND | 65.2/100Favorable setup100% evidence | LEADER | 26.6/35 Revenue 17.6% · PAT 46.4% · OPM change 3 pp 100% evidence | 13.8/25 ROCE 15.1% · OPM 27% 100% evidence | 11.9/20 P/E 42× · PEG 1.45 100% evidence | 12.9/20 RS sector -3.5% · RS bench 44.2% · 1Y 44.2%12 of 12 weeks ahead 100% evidence |
| Exact sum: 26.6 + 13.8 + 11.9 + 12.9 = 65.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4Accent Microcell LtdACCENTMIC | 64.8/100Mixed-positive evidence63% evidence | LEADER | 17.1/35 Revenue — · PAT — · OPM change -1 pp 26% evidence | 19.1/25 ROCE 24.9% · OPM 16% 95% evidence | 10.2/20 P/E 36.9× · PEG — 50% evidence | 18.4/20 RS sector 12.6% · RS bench 65.7% · 1Y 151.6%12 of 12 weeks ahead 100% evidence |
| Exact sum: 17.1 + 19.1 + 10.2 + 18.4 = 64.8 · Decision use: Price leads the evidence: RS versus the benchmark is 65.7%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 5Senores Pharmaceuticals LtdSENORES | 63.7/100Mixed-positive evidence75% evidence | LEADER | 31.7/35 Revenue 50.9% · PAT 92.7% · OPM change 5 pp 95% evidence | 14.8/25 ROCE 15.1% · OPM 30% 76% evidence | 9.6/20 P/E 49.4× · PEG — 15% evidence | 7.6/20 RS sector -6.3% · RS bench 38% · 1Y 90.3%12 of 12 weeks ahead 100% evidence |
| Exact sum: 31.7 + 14.8 + 9.6 + 7.6 = 63.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 6Corona Remedies LtdCORONA | 63.6/100Mixed-positive evidence73% evidence | BREAKING OUT | 20.6/35 Revenue 18% · PAT 19.3% · OPM change 2 pp 100% evidence | 20.7/25 ROCE 33.3% · OPM 22% 100% evidence | 12.3/20 P/E 61× · PEG 1.18 65% evidence | 10.0/20 RS sector — · RS bench — · 1Y —12 of 12 weeks ahead 0% evidence |
| Exact sum: 20.6 + 20.7 + 12.3 + 10 = 63.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 7Bliss GVS Pharma LtdBLISSGVS | 63.3/100Mixed-positive evidence82% evidence | LEADER | 28.1/35 Revenue 20.6% · PAT 25.7% · OPM change 7 pp 95% evidence | 15.0/25 ROCE 16.9% · OPM 27% 76% evidence | 6.4/20 P/E 54.4× · PEG — 50% evidence | 13.8/20 RS sector 63.8% · RS bench 128.5% · 1Y 368.1%12 of 12 weeks ahead 100% evidence |
| Exact sum: 28.1 + 15 + 6.4 + 13.8 = 63.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 8Ipca Laboratories LtdIPCALAB | 61.8/100Mixed-positive evidence82% evidence | LEADER | 24.9/35 Revenue 10.6% · PAT 68% · OPM change 6 pp 95% evidence | 15.9/25 ROCE 17% · OPM 24% 76% evidence | 12.3/20 P/E 36.4× · PEG — 50% evidence | 8.7/20 RS sector -15.4% · RS bench 28% · 1Y 36.8%11 of 12 weeks ahead 100% evidence |
| Exact sum: 24.9 + 15.9 + 12.3 + 8.7 = 61.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 9Emcure Pharmaceuticals Ltdthis pageEMCURE | 59.4/100Mixed-positive evidence75% evidence | LEADER | 25.6/35 Revenue 18.4% · PAT 32.2% · OPM change 1 pp 95% evidence | 18.1/25 ROCE 24% · OPM 21% 76% evidence | 10.6/20 P/E 35.9× · PEG — 15% evidence | 5.1/20 RS sector -18.5% · RS bench 23.1% · 1Y 45.3%11 of 12 weeks ahead 100% evidence |
| Exact sum: 25.6 + 18.1 + 10.6 + 5.1 = 59.4 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -18.5% and the one-year return is 45.3%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 10Granules India LtdGRANULES | 59.1/100Mixed-positive evidence100% evidence | LEADER | 26.8/35 Revenue 24.8% · PAT 38.1% · OPM change 3 pp 100% evidence | 15.3/25 ROCE 15.5% · OPM 23% 100% evidence | 10.0/20 P/E 36.4× · PEG 1.27 100% evidence | 7.0/20 RS sector -13.2% · RS bench 29.9% · 1Y 59.9%11 of 12 weeks ahead 100% evidence |
| Exact sum: 26.8 + 15.3 + 10 + 7 = 59.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 11Marksans Pharma LtdMARKSANS | 56.8/100Mixed-positive evidence87% evidence | BREAKING OUT | 24.9/35 Revenue 19.6% · PAT 48% · OPM change 9 pp 100% evidence | 16.2/25 ROCE 18.8% · OPM 25% 100% evidence | 6.8/20 P/E 29.6× · PEG 2.85 65% evidence | 8.9/20 RS sector -20.8% · RS bench 59.1% · 1Y 88.1%12 of 12 weeks ahead 70% evidence |
| Exact sum: 24.9 + 16.2 + 6.8 + 8.9 = 56.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 12Rubicon Research LtdRUBICON | 56.8/100Mixed-positive evidence73% evidence | BREAKING OUT | 22.6/35 Revenue 46.8% · PAT 91.4% · OPM change 2 pp 100% evidence | 18.2/25 ROCE 28.4% · OPM 24% 100% evidence | 6.0/20 P/E 96.3× · PEG 2.41 65% evidence | 10.0/20 RS sector — · RS bench — · 1Y 170.9%12 of 12 weeks ahead 0% evidence |
| Exact sum: 22.6 + 18.2 + 6 + 10 = 56.8 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression. | ||||||
| 13Ind-Swift Laboratories LtdINDSWFTLAB | 54.5/100Mixed-positive evidence87% evidence | LEADER | 22.1/35 Revenue 53.9% · PAT -74.3% · OPM change 14.6 pp 95% evidence | 4.9/25 ROCE 4.9% · OPM 17% 95% evidence | 7.5/20 P/E 54× · PEG — 50% evidence | 20.0/20 RS sector 73.1% · RS bench 145.3% · 1Y 288.4%12 of 12 weeks ahead 100% evidence |
| Exact sum: 22.1 + 4.9 + 7.5 + 20 = 54.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 14Caplin Point Laboratories LtdCAPLIPOINT | 54.3/100Mixed-positive evidence100% evidence | LEADER | 16.2/35 Revenue 15% · PAT 19.6% · OPM change 0 pp 100% evidence | 18.0/25 ROCE 24.2% · OPM 35% 100% evidence | 11.0/20 P/E 32.4× · PEG 1.52 100% evidence | 9.1/20 RS sector -6.9% · RS bench 39.9% · 1Y 21%12 of 12 weeks ahead 100% evidence |
| Exact sum: 16.2 + 18 + 11 + 9.1 = 54.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 15Ajanta Pharma LtdAJANTPHARM | 51.8/100Mixed-positive evidence100% evidence | LEADER | 19.4/35 Revenue 20.2% · PAT 22.2% · OPM change -1 pp 100% evidence | 20.1/25 ROCE 34.5% · OPM 26% 100% evidence | 6.9/20 P/E 39.1× · PEG 2.31 100% evidence | 5.4/20 RS sector -19.2% · RS bench 22.3% · 1Y 39.4%12 of 12 weeks ahead 100% evidence |
| Exact sum: 19.4 + 20.1 + 6.9 + 5.4 = 51.8 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression. | ||||||
| 16Fredun Pharmaceuticals Ltd539730 | 51.6/100Thin evidence · provisional50% evidence | 16.8/35 Revenue — · PAT — · OPM change 0 pp 24% evidence | 14.8/25 ROCE 21.3% · OPM 14% 76% evidence | 9.1/20 P/E 58.4× · PEG — 15% evidence | 10.9/20 RS sector -29% · RS bench 133.6% · 1Y 26%0 of 6 weeks ahead to 2026-08-16 100% evidence | |
| Exact sum: 16.8 + 14.8 + 9.1 + 10.9 = 51.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 17RPG Life Sciences LtdRPGLIFE | 51.1/100Mixed-positive evidence93% evidence | LEADER | 9.4/35 Revenue 11.9% · PAT -34.1% · OPM change 1 pp 100% evidence | 17.6/25 ROCE 25.7% · OPM 22% 100% evidence | 11.5/20 P/E 43.2× · PEG 1.43 65% evidence | 12.6/20 RS sector -11.3% · RS bench 34.8% · 1Y 25%11 of 12 weeks ahead 100% evidence |
| Exact sum: 9.4 + 17.6 + 11.5 + 12.6 = 51.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 18Strides Pharma Science LtdSTAR | 49.9/100Mixed-negative evidence75% evidence | TURNING | 19.2/35 Revenue 8.1% · PAT 79.1% · OPM change -1 pp 95% evidence | 13.2/25 ROCE 18.3% · OPM 18% 76% evidence | 11.5/20 P/E 18.8× · PEG — 15% evidence | 6.0/20 RS sector -18.6% · RS bench 23.7% · 1Y 36%5 of 12 weeks ahead 100% evidence |
| Exact sum: 19.2 + 13.2 + 11.5 + 6 = 49.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 19Akums Drugs & Pharmaceuticals LtdAKUMS | 49.4/100Mixed-negative evidence75% evidence | LEADER | 11.9/35 Revenue 9.2% · PAT -15.8% · OPM change 2 pp 95% evidence | 10.7/25 ROCE 14.9% · OPM 15% 76% evidence | 10.0/20 P/E 42.3× · PEG — 15% evidence | 16.8/20 RS sector 3.7% · RS bench 54.1% · 1Y 72%12 of 12 weeks ahead 100% evidence |
| Exact sum: 11.9 + 10.7 + 10 + 16.8 = 49.4 · Decision use: Price leads the evidence: RS versus the benchmark is 54.1%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 20Wockhardt LtdWOCKPHARMA | 49.4/100Mixed-negative evidence74% evidence | TURNING | 24.0/35 Revenue 18.4% · PAT 100% · OPM change 11 pp 74% evidence | 5.4/25 ROCE 7.5% · OPM 21% 100% evidence | 8.8/20 P/E 92.3× · PEG — 15% evidence | 11.2/20 RS sector -2% · RS bench 46.5% · 1Y 50.5%11 of 12 weeks ahead 100% evidence |
| Exact sum: 24 + 5.4 + 8.8 + 11.2 = 49.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 21Zydus Lifesciences LtdZYDUSLIFE | 48.9/100Mixed-negative evidence100% evidence | LEADER | 10.5/35 Revenue 21.1% · PAT -2.5% · OPM change -8 pp 100% evidence | 16.9/25 ROCE 21.1% · OPM 24% 100% evidence | 15.6/20 P/E 24.7× · PEG 1.23 100% evidence | 5.9/20 RS sector -18.8% · RS bench 23.4% · 1Y 16.1%9 of 12 weeks ahead 100% evidence |
| Exact sum: 10.5 + 16.9 + 15.6 + 5.9 = 48.9 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 22Suven Life Sciences LtdSUVEN | 47.8/100Mixed-negative evidence67% evidence | LEADER | 19.6/35 Revenue 25% · PAT -80% · OPM change -997 pp 74% evidence | 2.3/25 ROCE -79.5% · OPM — 84% evidence | 10.0/20 P/E — · PEG — 0% evidence | 15.9/20 RS sector 4.2% · RS bench 52% · 1Y 49.3%12 of 12 weeks ahead 100% evidence |
| Exact sum: 19.6 + 2.3 + 10 + 15.9 = 47.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 23Kilitch Drugs (India) LtdKILITCH | 47.0/100Mixed-negative evidence87% evidence | TURNING | 11.5/35 Revenue 14% · PAT 9.3% · OPM change -1 pp 95% evidence | 9.4/25 ROCE 13.4% · OPM 6.5% 95% evidence | 14.4/20 P/E 26.1× · PEG — 50% evidence | 11.7/20 RS sector -13.3% · RS bench 33.1% · 1Y 24.6%8 of 12 weeks ahead 100% evidence |
| Exact sum: 11.5 + 9.4 + 14.4 + 11.7 = 47 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 24Jagsonpal Pharmaceuticals LtdJAGSNPHARM | 46.9/100Mixed-negative evidence87% evidence | LEADER | 12.7/35 Revenue 3.2% · PAT -24.6% · OPM change 2 pp 95% evidence | 16.8/25 ROCE 22.7% · OPM 21% 95% evidence | 11.7/20 P/E 34× · PEG — 50% evidence | 5.7/20 RS sector -21.3% · RS bench 20% · 1Y -0.3%11 of 12 weeks ahead 100% evidence |
| Exact sum: 12.7 + 16.8 + 11.7 + 5.7 = 46.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 25J B Chemicals & Pharmaceuticals LtdJBCHEPHARM | 44.3/100Mixed-negative evidence96% evidence | 9.3/35 Revenue 5.9% · PAT 7.4% · OPM change -2 pp 88% evidence | 20.9/25 ROCE 25.4% · OPM 22% 100% evidence | 4.3/20 P/E 53.8× · PEG 2.34 100% evidence | 9.8/20 RS sector -8.2% · RS bench 23.5% · 1Y 40.5%2 of 2 weeks ahead to 2026-07-19 100% evidence | |
| Exact sum: 9.3 + 20.9 + 4.3 + 9.8 = 44.3 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression. | ||||||
| 26Gufic BioSciences LtdGUFICBIO | 41.6/100Mixed-negative evidence94% evidence | BREAKING OUT | 20.7/35 Revenue 16.6% · PAT 17.7% · OPM change 3 pp 100% evidence | 10.1/25 ROCE 12.3% · OPM 18% 100% evidence | 3.5/20 P/E 57.9× · PEG 4.78 100% evidence | 7.3/20 RS sector -21.1% · RS bench 26.1% · 1Y 14.5%12 of 12 weeks ahead 70% evidence |
| Exact sum: 20.7 + 10.1 + 3.5 + 7.3 = 41.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 27Alembic Pharmaceuticals LtdAPLLTD | 41.4/100Mixed-negative evidence94% evidence | BREAKING OUT | 14.1/35 Revenue 14.1% · PAT 14.6% · OPM change -1 pp 100% evidence | 8.8/25 ROCE 12.6% · OPM 15% 100% evidence | 13.2/20 P/E 22.8× · PEG 1.74 100% evidence | 5.3/20 RS sector -26.6% · RS bench 9.7% · 1Y -9.9%6 of 12 weeks ahead 70% evidence |
| Exact sum: 14.1 + 8.8 + 13.2 + 5.3 = 41.4 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 28Aurobindo Pharma LtdAUROPHARMA | 39.8/100Mixed-negative evidence100% evidence | LEADER | 14.6/35 Revenue 9.1% · PAT 9.5% · OPM change 1 pp 100% evidence | 12.7/25 ROCE 12.9% · OPM 21% 100% evidence | 6.0/20 P/E 26× · PEG 2.67 100% evidence | 6.5/20 RS sector -14.7% · RS bench 28.4% · 1Y 53%10 of 12 weeks ahead 100% evidence |
| Exact sum: 14.6 + 12.7 + 6 + 6.5 = 39.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 29Bafna Pharmaceuticals LtdBAFNAPH | 39.2/100Mixed-negative evidence60% evidence | BREAKING OUT | 11.1/35 Revenue -3.1% · PAT -5.8% · OPM change -11.3 pp 95% evidence | 7.3/25 ROCE 11.9% · OPM 3.4% 76% evidence | 8.6/20 P/E 106× · PEG — 15% evidence | 12.2/20 RS sector — · RS bench 107.9% · 1Y —5 of 5 weeks ahead 25% evidence |
| Exact sum: 11.1 + 7.3 + 8.6 + 12.2 = 39.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 30Indoco Remedies LtdINDOCO | 38.2/100Thin evidence · provisional58% evidence | BREAKING OUT | 18.9/35 Revenue 11.9% · PAT 100% · OPM change 5 pp 71% evidence | 4.3/25 ROCE 1% · OPM 9% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 5.0/20 RS sector -34.4% · RS bench 12.5% · 1Y -15.7%8 of 11 weeks ahead 70% evidence |
| Exact sum: 18.9 + 4.3 + 10 + 5 = 38.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 31Bharat Parenterals LtdBPLPHARMA | 35.7/100Thin evidence · provisional58% evidence | 11.6/35 Revenue -11.2% · PAT 16% · OPM change -2.8 pp 71% evidence | 4.0/25 ROCE -1.9% · OPM 9.1% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 10.1/20 RS sector -13.5% · RS bench 54.8% · 1Y 44.1%1 of 12 weeks ahead 70% evidence | |
| Exact sum: 11.6 + 4 + 10 + 10.1 = 35.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 32Torrent Pharmaceuticals LtdTORNTPHARM | 35.5/100Mixed-negative evidence100% evidence | LEADER | 15.3/35 Revenue 32.9% · PAT 7.7% · OPM change 2 pp 100% evidence | 14.9/25 ROCE 15.2% · OPM 34% 100% evidence | 1.0/20 P/E 85× · PEG 5.11 100% evidence | 4.3/20 RS sector -21.1% · RS bench 19.6% · 1Y 37.3%11 of 12 weeks ahead 100% evidence |
| Exact sum: 15.3 + 14.9 + 1 + 4.3 = 35.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 33Zim Laboratories LtdZIMLAB | 34.5/100Adverse evidence79% evidence | LEADER | 8.7/35 Revenue 7.5% · PAT -60.6% · OPM change -3.3 pp 71% evidence | 6.2/25 ROCE 4.8% · OPM 2.6% 95% evidence | 6.3/20 P/E 201× · PEG — 50% evidence | 13.3/20 RS sector 6% · RS bench 56.4% · 1Y 83%11 of 12 weeks ahead 100% evidence |
| Exact sum: 8.7 + 6.2 + 6.3 + 13.3 = 34.5 · Decision use: Price leads the evidence: RS versus the benchmark is 56.4%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 34Jubilant Pharmova LtdJUBLPHARMA | 33.7/100Adverse evidence93% evidence | TURNING | 8.7/35 Revenue 16.3% · PAT -23% · OPM change -4 pp 100% evidence | 5.8/25 ROCE 9% · OPM 11% 100% evidence | 13.4/20 P/E 44× · PEG 1.17 65% evidence | 5.8/20 RS sector -27.9% · RS bench 11.8% · 1Y -2.7%5 of 12 weeks ahead 100% evidence |
| Exact sum: 8.7 + 5.8 + 13.4 + 5.8 = 33.7 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Emcure Pharmaceuticals Ltd's share price today?
Emcure Pharmaceuticals Ltd trades at ₹1,951, +51.9% over the past year. The company is valued at ₹37,005 Cr. The stock sits at 92% of its 52-week range of ₹1,355–₹2,004, +14.0% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 64 weeks in. — as of 25 September 2026.
What were Emcure Pharmaceuticals Ltd's latest quarterly results?
Emcure Pharmaceuticals Ltd reported revenue of ₹2,580 Cr and net profit of ₹292 Cr for the Jun 26 quarter. Revenue rose 22.8% and profit rose 35.8% year on year. Earnings per share were ₹15.50. The operating margin was 21.0%, 1.0 pp higher than a year earlier. — as of 25 September 2026.
What is Emcure Pharmaceuticals Ltd's revenue?
Emcure Pharmaceuticals Ltd reported revenue of ₹2,580 Cr in the Jun 26 quarter, +22.8% year on year. For the full FY26 fiscal year, revenue was ₹9,204 Cr (+16.6%). Over the last 7 years revenue compounded at 10.0% a year. — as of 25 September 2026.
What is Emcure Pharmaceuticals Ltd's profit?
Emcure Pharmaceuticals Ltd earned ₹292 Cr of net profit in the Jun 26 quarter, +35.8% year on year — the 9th straight quarter of growth. Full-year FY26 profit was ₹941 Cr. The operating margin ran 21.0% in the latest quarter. — as of 25 September 2026.
What is Emcure Pharmaceuticals Ltd's market cap?
Emcure Pharmaceuticals Ltd's market capitalisation is ₹37,005 Cr at a share price of ₹1,951. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 25 September 2026.
What is Emcure Pharmaceuticals Ltd's P/E ratio?
Emcure Pharmaceuticals Ltd trades at a P/E of 35.9×, at the 57th percentile of its own 2-year range, against a long-run median of 35.2×. This is a comparison with the stock's own history, not a value call — as of 25 September 2026.
Does Emcure Pharmaceuticals Ltd pay a dividend?
Yes — Emcure Pharmaceuticals Ltd's dividend payout was 7% of profit in FY26, and it recorded a payout in each of its last 8 reported fiscal years. This page holds the payout ratio, not a per-share amount. — as of 25 September 2026.
Is Emcure Pharmaceuticals Ltd overvalued?
On its own history, Emcure Pharmaceuticals Ltd looks mid-range: its P/E of 35.9× sits at the 57th percentile of its 2-year range (long-run median 35.2×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 25 September 2026.
Is Emcure Pharmaceuticals Ltd growing?
Yes — Emcure Pharmaceuticals Ltd is growing: latest-quarter revenue +22.8% year on year, profit +35.8%, and the margin +1.0 pp at 21.0%. The 7-year compound rates are 10.0% (revenue) and 24.0% (profit). The earnings engine currently reads: improving — as of 25 September 2026.
How is Emcure Pharmaceuticals Ltd performing?
Emcure Pharmaceuticals Ltd is in a confirmed uptrend, 64 weeks in. Its latest quarter's revenue rose 22.8% and profit rose 35.8% year on year. Against the NIFTY 500 it has been ahead on a trailing-13-week view for 19 weeks. This describes what the data did, not a rating. — as of 25 September 2026.
What stage is Emcure Pharmaceuticals Ltd in?
Consistent — revenue and profit growth have stayed positive through the window, with ROCE at 24.0% and holding. The read comes from the last 12 quarters of growth (revenue growth +22.8% latest, profit growth +35.8% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 25 September 2026.
Is Emcure Pharmaceuticals Ltd in an uptrend?
Yes — the price is in a confirmed uptrend (week 64 of stage 2), trading +14.0% versus its 200-day average and at 92% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 25 September 2026.
Is Emcure Pharmaceuticals Ltd beating the market?
On recent form, yes — Emcure Pharmaceuticals Ltd has been ahead of the NIFTY 500 on a trailing-13-week view for 19 straight weeks, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 2.2 years the stock moved +43% against the NIFTY 500's −3% — ahead of the index over the full window. — as of 25 September 2026.
Will Emcure Pharmaceuticals Ltd's share price go up?
This page publishes no price forecast for Emcure Pharmaceuticals Ltd. What it measures instead: the share price is ₹1,951, the price is in a confirmed uptrend 64 weeks in. Its P/E of 35.9× sits at the 57th percentile of its own 2-year range. — as of 25 September 2026.
Who owns Emcure Pharmaceuticals Ltd?
Promoters hold 77.8% of Emcure Pharmaceuticals Ltd, foreign institutions 4.9%, domestic institutions 8.5% and the public 8.8% (latest quarter). The biggest move on the register over the last two years: Domestic institutions added 4.5 points over 7 quarters. — as of 25 September 2026.
Does Emcure Pharmaceuticals Ltd have too much debt?
It is moderate — Emcure Pharmaceuticals Ltd's debt-to-equity is 0.31, and operating profit covers the interest bill 12×. FY26 borrowings were ₹1,521 Cr against equity of ₹4,950 Cr. Read the returns on this page with that leverage in mind — as of 25 September 2026.
What is Emcure Pharmaceuticals Ltd's capex?
Emcure Pharmaceuticals Ltd spent ₹2,145 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹633 Cr, with ₹273 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 25 September 2026.
What is Emcure Pharmaceuticals Ltd's cash flow?
Emcure Pharmaceuticals Ltd generated ₹944 Cr of operating cash flow in FY26 and ₹311 Cr of free cash flow after ₹633 Cr of capital spending. Reported profit that year was ₹941 Cr, so operating cash ran ahead of profit. Cash-flow resolution for India is annual. — as of 25 September 2026.
Is Emcure Pharmaceuticals Ltd's profit real cash?
Yes — over the last 3 fiscal years, 133% of Emcure Pharmaceuticals Ltd's reported profit arrived as operating cash. Though the latest year ran at 100% — the trend is the thing to watch. In FY26, operating cash was ₹944 Cr against reported profit of ₹941 Cr. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 25 September 2026.
Where is Emcure Pharmaceuticals Ltd in its business cycle?
Emcure Pharmaceuticals Ltd's FY26 operating margin was 19.0%, against a 8-year band of 14.0%–24.0%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 21.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 25 September 2026.
What growth does Emcure Pharmaceuticals Ltd's price assume?
At its price on 24 August 2026, Emcure Pharmaceuticals Ltd was priced for profit growth of about 19.7% a year. Profit itself has compounded 24.0% a year over the past 7 years. The figure reads the multiple backwards: the growth a buyer at that price was already paying for. — as of 25 September 2026.
What could break the Emcure Pharmaceuticals Ltd story?
Biggest watch item: the price is already 64 weeks into its uptrend — timing risk, not thesis risk. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 25 September 2026.
Is Emcure Pharmaceuticals Ltd a stock worth studying right now?
This is not investment advice. The machine read: Emcure Pharmaceuticals Ltd's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it. The sharpest open question: the next one or two quarters of delivery. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 25 September 2026.
Not SEBI Registered !! Not Investment advice !!